Abstract Background Acquired Hemophilia A (AHA) is a rare autoimmune disorder
associated with the development of autoantibodies against factor VIII (FVIII). Although …

ABSTRACT Introduction: Hemophilia A and B are X-linked recessive disorders caused by
the deficiency of factor VIII or factor IX, respectively. Bleeding episodes are treated with …

Development of inhibitory antibodies to coagulation factor VIII (fVIII) is the primary obstacle
to the treatment of hemophilia A in the developed world. This adverse reaction occurs in 20 …

Introduction Acquired haemophilia (AH) is a rare disorder caused by autoantibodies against
factor VIII. Aim The Hemostasis & Thrombosis Research Society (HTRS) Registry was used …

Patients with acquired hemophilia A (AHA) often present in an emergency setting to
physicians not specialized in bleeding disorders.[1] If symptoms and laboratory signs are …

For patients with hemophilia A, replacement of deficient factor VIII (FVIII) using plasma-
derived or recombinant FVIII (rFVIII) products to restore hemostatic control can reduce …

The development of inhibitors and the need for frequent venous access for FVIII injection are
major challenges in current haemophilia treatment. Presently available recombinant FVIII …

Background: Although routine supplementation of exogenous factor VIII (FVIII) effectively
prevents bleeding complications in hemophilia A patients, the development of FVIII inhibitors …

Current management of hemophilia A includes prophylaxis with factor VIII (FVIII)
replacement every 2 to 3 days. BAX 855, Baxalta's pegylated full-length recombinant FVIII …

Background BAY 94‐9027 is a B‐domain‐deleted recombinant factor VIII (rFVIII) with site‐
specific attachment of poly (ethylene glycol) that has shown an extended half‐life in animal …